The centralized procurement of medical consumables has been further expanded. Hebei Province has launched a centralized volume-based procurement of 25 types of medical consumables, and the official quotation has been initiated

Hebei Province is about to carry out centralized volume-based procurement of 25 types of medical consumables, and the official quotations will be available on November 20th.

Let's first take a look at the specific varieties of this centralized procurement: 25 procurement varieties such as non-vascular interventional universal biopsy needles, infusion ports, and lung nodule positioning puncture devices. To be honest, this list is much richer than we expected.

It is particularly worth noting that products such as ophthalmic silicone oil, ophthalmic heavy water, and titanium joints for peritoneal dialysis tubes, which are rarely seen on the centralized procurement list, are also included. This indicates that the scope of centralized procurement is expanding from common consumables to more specialized sub-sectors.

In terms of field distribution, this centralized procurement covers multiple specialized fields such as ophthalmology, digestive intervention, coronary intervention, peripheral intervention, and neurointervention. This means that almost no clinical department can stay out of it.

The official quotation time for centralized procurement is set from 9:00 to 15:00 on November 20, 2025, which lasts for six hours.。

The uniqueness of the Hebei model: Why does it always "take an unconventional path"?

When it comes to the centralized procurement model in Hebei, it is indeed very distinctive. Since 2022, Hebei has been conducting volume-based procurement of consumables independently or in the lead for several consecutive years, and each time there have been some "newcomers".

The advantage of this model lies in its ability to quickly cover more varieties, but at the same time, it also places higher demands on the adaptability of enterprises. Just like when we doctors perform surgeries, we not only need to master the conventional surgical procedures but also be able to handle various special situations.

Based on past data, the price reduction of some varieties in the centralized procurement in Hebei Province has been relatively large, with some even exceeding 90%. Whether a similar "broken price" will occur this time remains to be seen.

The national centralized procurement boom: Six major alliances are advancing in unison.

In addition to the individual action taken by Hebei Province, there are also six major alliance centralized procurement projects being advanced simultaneously recently:

The centralized procurement of vena cava filters and ablation electrodes led by Heilongjiang Province has alliance members covering 23 provincial administrative regions. This is a large alliance.

The procurement documents of the structural heart disease occluder alliance led by Fujian Province have been released. This time, it is a truly national alliance.

The centralized procurement of high-frequency electrosurgical knives and neutral electrodes led by Hunan, the centralized procurement of traditional Chinese medicine needles led by Guangxi, and the centralized procurement of ureteral stents led by Chongqing are all in the stage of soliciting opinions.

The inter-provincial alliance centralized procurement of heart valves led by Gansu Province is also being actively advanced, with varieties including biological valves, mechanical valves and interventional valves.

This trend of multiple alliances advancing in parallel indicates that centralized procurement has entered a regular and institutionalized stage.

Digital Consumables Centralized Procurement: An Innovative Practice of Cloud Film.

There is another highlight worth noting in this centralized procurement - digital consumables products have also begun to be included in the centralized procurement scope.

Cloud film centralized procurement has been carried out in many places such as Guizhou, Henan and Ningxia, which is an innovative integration of medical digitalization and centralized procurement. Under the background of promoting mutual recognition of examination and test results in medical institutions, cloud film centralized procurement provides technical support for achieving image sharing on a regional and even national scale.

This can not only reduce the procurement and storage costs of film consumables, but also accelerate the pace of smart hospital construction. In a sense, this is promoting the digital transformation of the medical industry through centralized procurement.

Enterprise response strategy: Transform and upgrade for survival.

In the face of the continuous impact of centralized procurement, enterprises are also actively adjusting their strategies.

According to data from Guojin Securities, the revenue of the medical consumables sector in the third quarter of 2025 decreased slightly by 0.50% year-on-year. Against the backdrop of the nationwide promotion of DRG policies, some surgical demands have indeed faced short-term pressure.

Lepu Medical's approach is quite representative: on the one hand, it actively manages the inventory of cardiovascular implantable and interventional devices through channels to prepare for centralized procurement; On the other hand, it actively explores emerging businesses such as medical aesthetics, innovative drugs, neuroregulation/brain-computer interfaces.。

Although the Health Protection division of Lanfan Medical suffered losses, its cardiovascular and cerebrovascular division achieved a revenue of over 1 billion yuan, with a year-on-year growth of more than 20%. Its TAV system has obtained the EU CE certification, and the sales volume of its valve products has reached a record high.

These cases demonstrate that in the era of centralized procurement, enterprises should not only focus on their core business but also have the courage to explore new growth points.

The future of the consumables market: Value return is the main theme.

In the long run, centralized procurement is driving the medical consumables market to shift from "price competition" to "value-based healthcare".

For clinicians, this means that we need to pay more attention to the clinical efficacy and cost-effectiveness of consumables, rather than just the brand or price.

For hospital management, how to balance medical quality and cost control has become a subject that requires continuous exploration.

For patients, the price reduction brought about by centralized procurement is undoubtedly a good thing, but we also need to ensure product quality and supply stability.